Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EXIST: mXELIRI vs FOLFIRI + Bevacizumab in mCRC
NCT04247984Phase 2Completed
- Sponsor
- Chinese Academy of Medical Sciences
- Start
- May 2018
- Primary completion
- Apr 2021
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of capecitabine in metastatic colorectal cancer (mCRC), sponsored by Chinese Academy of Medical Sciences. Started May 2018; status: completed.
02
Drugs
capecitabine
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT04247984.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04247984.